- Orchestra BioMed to Participate in Jefferies Global Healthcare Conference
- Orchestra BioMed Reports First Quarter 2024 Financial Results and Provides a Business Update
- Orchestra BioMed Announces AVIM Therapy Global Intellectual Property Estate Reaches 110 Issued Patents
- Orchestra BioMed to Host In-Person R&D Day in New York on AVIM Therapy Program in Hypertensive Pacemaker Patients on June 11, 2024
- Orchestra BioMed Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update
- Orchestra BioMed Announces Appointment of Medical Device Industry Expert David Pacitti to Board of Directors
- Orchestra BioMed Demonstrates Strength of Cardiovascular Pipeline with Virtue® SAB and AVIM Therapy Presentations at CRT 2024 Annual Meeting
- Orchestra BioMed to Participate in Upcoming Investor Conferences
- Orchestra BioMed Announces Presentation of Results from Clinical Study Demonstrating Favorable Hemodynamic Effects of AVIM Therapy In Hypertensive Pacemaker Patients
- Orchestra BioMed Presents New Data Showing Sustained Clinically Meaningful Reduction in 24-Hour Ambulatory Systolic Blood Pressure in Hypertensive Pacemaker Patients Treated with AVIM Therapy for Over 3 Years
More ▼
Key statistics
On Tuesday, Orchestra Biomed Holdings Inc (OBIO:NMQ) closed at 6.97, 65.17% above the 52 week low of 4.22 set on Apr 25, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 5.24 |
---|---|
High | 7.25 |
Low | 4.85 |
Bid | 6.41 |
Offer | 6.89 |
Previous close | 6.97 |
Average volume | 56.27k |
---|---|
Shares outstanding | 35.79m |
Free float | 21.33m |
P/E (TTM) | -- |
Market cap | 249.45m USD |
EPS (TTM) | -1.47 USD |
Data delayed at least 15 minutes, as of May 28 2024 21:00 BST.
More ▼